Metabolic Syndrome-Parkinson's Disease Axis Clinical Trial

Metabolic Syndrome-Parkinson's Disease Clinical Trial Design

Experiment Overview

Hypothesis: Metabolic syndrome modulation through [GLP-1 receptor](/entities/glp1-receptor) agonist therapy will improve metabolic parameters, reduce neuroinflammation, and slow disease progression in [Parkinson's disease](/diseases/parkinsons-disease) patients with metabolic dysfunction.

Study Design

Metabolic Syndrome-Parkinson's Disease Clinical Trial Design

Experiment Overview

Hypothesis: Metabolic syndrome modulation through [GLP-1 receptor](/entities/glp1-receptor) agonist therapy will improve metabolic parameters, reduce neuroinflammation, and slow disease progression in [Parkinson's disease](/diseases/parkinsons-disease) patients with metabolic dysfunction.

Study Design

Population

• Sample Size: 200 participants (100 treatment, 100 placebo)
• Inclusion Criteria:
• Age 50-75 years
• PD diagnosis (UK Brain Bank criteria)
• Hoehn & Yahr stage 1-3
• Disease duration 1-8 years
• Evidence of metabolic dysfunction (≥2 of: BMI ≥28, HbA1c 5.7-6.9%, triglycerides >150 mg/dL, HDL <40 mg/dL men/<50 mg/dL women, BP >130/85 mmHg)
• Stable dopaminergic therapy for ≥1 month
• Exclusion Criteria:
• Type 1 or Type 2 diabetes on insulin therapy
• History of pancreatitis
• Current GLP-1 agonist use
• Severe renal or hepatic impairment
• Active cancer

Intervention Arms

• Subcutaneous injection
• Standard diabetes dosing for neuroprotection

Duration

• 12-month treatment period
• 6-month follow-up off intervention

Endpoints

Primary Endpoints

Secondary Endpoints

• PDQ-39
• SCOPA-AUT (autonomic dysfunction)
• MoCA (cognitive function)
• Epworth Sleepiness Scale

• DAT-SPECT (dopaminergic transporter binding) at baseline and 12 months
• SWI (iron deposition) in substantia nigra

• [Alpha-synuclein](/proteins/alpha-synuclein) seed amplification assay (αSyn-SAA) in CSF](/proteins)
• [Neurofilament light](/biomarkers/neurofilament-light-chain-nfl) chain (NfL) in plasma

Exploratory Endpoints

• Gut [microbiome](/entities/microbiome) composition (16S rRNA sequencing)
• Peripheral blood mononuclear cell (PBMC) mitochondrial function
• [Autophagy](/entities/autophagy) markers in monocytes

Statistical Analysis

Power Calculation

• 80% power to detect 3.5-point difference in MDS-UPDRS III (α=0.05)
• Assuming 20% dropout
• Based on exenatide trial effect size (4.5 points)

Analysis Plan

• Intent-to-treat analysis
• Mixed-effects model for repeated measures
• Stratification by metabolic syndrome severity
• Corrections for multiple comparisons

Risks and Mitigations

| Risk | Mitigation |
|------|------------|
| GI side effects (nausea, vomiting) | Gradual titration, antiemetic as needed |
| Pancreatitis | Exclusion of high-risk patients, lipase monitoring |
| Hypoglycemia | Monitor fasting glucose, exclude intensive insulin users |
| Thyroid C-cell tumors | Exclusion of patients with family history of medullary thyroid carcinoma |

Budget Estimate

• Personnel: $600,000
• Study drug/placebo: $400,000
• Lab assays: $300,000
• Imaging (DAT-SPECT, MRI): $400,000
• Patient compensation: $200,000
• Regulatory/IRB: $100,000
• Contingency (20%): $400,000
• Total: ~$2,400,000

Timeline

| Milestone | Timepoint |
|-----------|-----------|
| IRB submission | Month 0 |
| IND application | Month 2 |
| Recruitment start | Month 6 |
| Last patient enrolled | Month 18 |
| Last patient completed | Month 30 |
| Primary analysis | Month 34 |

Success Criteria

• Primary: Statistically significant improvement in MDS-UPDRS III AND improvement in metabolic parameters
• Secondary: Reduction in neuroinflammatory markers, preservation of DAT binding
• Significance: Would provide evidence for metabolic modulation as disease-modifying therapy in PD

Subgroup Analyses

Mechanistic Validation

To validate the hypothesis mechanistically:

References

Pathway Diagram

The following diagram shows the key molecular relationships involving Metabolic Syndrome-Parkinson's Disease Axis Clinical Trial discovered through SciDEX knowledge graph analysis: